JP2017149767A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017149767A5 JP2017149767A5 JP2017092572A JP2017092572A JP2017149767A5 JP 2017149767 A5 JP2017149767 A5 JP 2017149767A5 JP 2017092572 A JP2017092572 A JP 2017092572A JP 2017092572 A JP2017092572 A JP 2017092572A JP 2017149767 A5 JP2017149767 A5 JP 2017149767A5
- Authority
- JP
- Japan
- Prior art keywords
- dermatitis
- erythema
- flushing
- facial
- rosacea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010015150 Erythema Diseases 0.000 description 27
- 231100000321 erythema Toxicity 0.000 description 18
- 208000003251 Pruritus Diseases 0.000 description 12
- 241001303601 Rosacea Species 0.000 description 12
- 201000008937 atopic dermatitis Diseases 0.000 description 12
- 201000004700 rosacea Diseases 0.000 description 12
- 206010016825 Flushing Diseases 0.000 description 10
- 201000004624 Dermatitis Diseases 0.000 description 9
- 230000010339 dilation Effects 0.000 description 9
- 208000002874 Acne Vulgaris Diseases 0.000 description 8
- 206010012438 Dermatitis atopic Diseases 0.000 description 8
- 206010000496 acne Diseases 0.000 description 8
- 208000010668 atopic eczema Diseases 0.000 description 8
- 208000017520 skin disease Diseases 0.000 description 7
- 206010015037 epilepsy Diseases 0.000 description 6
- 230000001815 facial effect Effects 0.000 description 6
- 238000011010 flushing procedure Methods 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 description 4
- 206010012434 Dermatitis allergic Diseases 0.000 description 4
- 206010012442 Dermatitis contact Diseases 0.000 description 4
- 206010012456 Dermatitis exfoliative generalised Diseases 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 4
- 206010018691 Granuloma Diseases 0.000 description 4
- 206010060800 Hot flush Diseases 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 4
- 208000006877 Insect Bites and Stings Diseases 0.000 description 4
- 206010051246 Photodermatosis Diseases 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 206010037549 Purpura Diseases 0.000 description 4
- 241001672981 Purpura Species 0.000 description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 4
- 206010041955 Stasis dermatitis Diseases 0.000 description 4
- 206010042496 Sunburn Diseases 0.000 description 4
- 206010043189 Telangiectasia Diseases 0.000 description 4
- 208000024780 Urticaria Diseases 0.000 description 4
- 206010046996 Varicose vein Diseases 0.000 description 4
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 208000009621 actinic keratosis Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 208000010247 contact dermatitis Diseases 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 230000009245 menopause Effects 0.000 description 4
- 230000008845 photoaging Effects 0.000 description 4
- 230000001107 psychogenic effect Effects 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 208000009056 telangiectasis Diseases 0.000 description 4
- 208000027185 varicose disease Diseases 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- 206010016936 Folliculitis Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 206010047141 Vasodilatation Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000011474 orchiectomy Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 2
- SIDBSMXMBWXFQV-UHFFFAOYSA-N 7-(1h-imidazol-5-ylmethyl)-5,6,7,8-tetrahydroquinoline Chemical compound C1CC2=CC=CN=C2CC1CC1=CNC=N1 SIDBSMXMBWXFQV-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- SIDBSMXMBWXFQV-JTQLQIEISA-N (7s)-7-(1h-imidazol-5-ylmethyl)-5,6,7,8-tetrahydroquinoline Chemical compound C([C@H]1CC2=NC=CC=C2CC1)C1=CNC=N1 SIDBSMXMBWXFQV-JTQLQIEISA-N 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 208000009675 Perioral Dermatitis Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558104P | 2011-11-10 | 2011-11-10 | |
| US61/558,104 | 2011-11-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541225A Division JP6359456B2 (ja) | 2011-11-10 | 2012-11-08 | ７−（１ｈ−イミダゾール−４−イルメチル）−５，６，７，８−テトラヒドロキノリンを含む肌の疾患および状態を治療するための医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017149767A JP2017149767A (ja) | 2017-08-31 |
| JP2017149767A5 true JP2017149767A5 (cg-RX-API-DMAC7.html) | 2018-06-21 |
| JP6526737B2 JP6526737B2 (ja) | 2019-06-05 |
Family
ID=47178364
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541225A Active JP6359456B2 (ja) | 2011-11-10 | 2012-11-08 | ７−（１ｈ−イミダゾール−４−イルメチル）−５，６，７，８−テトラヒドロキノリンを含む肌の疾患および状態を治療するための医薬組成物 |
| JP2017092572A Active JP6526737B2 (ja) | 2011-11-10 | 2017-05-08 | ７−（１ｈ−イミダゾール−４−イルメチル）−５，６，７，８−テトラヒドロキノリンを含む肌の疾患および状態を治療するための医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541225A Active JP6359456B2 (ja) | 2011-11-10 | 2012-11-08 | ７−（１ｈ−イミダゾール−４−イルメチル）−５，６，７，８−テトラヒドロキノリンを含む肌の疾患および状態を治療するための医薬組成物 |
Country Status (22)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9283217B2 (en) | 2011-11-10 | 2016-03-15 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
| RU2015148910A (ru) * | 2013-05-06 | 2017-06-13 | Аллерган, Инк. | Альфа-адренергические агонисты для лечения повреждения тканей |
| FR3061434B1 (fr) * | 2017-01-04 | 2019-07-12 | Pierre Fabre Dermo-Cosmetique | Composition cosmetique comprenant une association d'huile de pongamia et de pentylene glycol 4-t-butylcyclohexanol pour lutter contre la rosacee |
| RU2727695C1 (ru) * | 2020-02-13 | 2020-07-22 | Мурад Умарович Магомедов | Способ комплексного лечения ринофимы |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1075265B1 (en) * | 1998-05-08 | 2006-03-08 | The University Of Miami | Use of tetracyclines for treating meibomian gland disease |
| WO2004073708A1 (en) * | 1998-12-17 | 2004-09-02 | Dean Thomas R | Brinzolamide and brimonidine for treating ocular conditions |
| US20010049369A1 (en) * | 2000-02-10 | 2001-12-06 | Jablonski Monica M. | Brimonidine compositions and methods for retinal degeneration |
| US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
| US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
| US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
| US6680062B2 (en) | 2001-10-05 | 2004-01-20 | Color Access, Inc. | Anti-irritating rosacea treatment |
| US7030149B2 (en) * | 2002-04-19 | 2006-04-18 | Allergan, Inc. | Combination of brimonidine timolol for topical ophthalmic use |
| US20040146539A1 (en) * | 2003-01-24 | 2004-07-29 | Gupta Shyam K. | Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US20050020600A1 (en) * | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| AU2004293105B2 (en) * | 2003-11-20 | 2010-09-09 | Othera Holding, Inc. | Amelioration of macular degeneration and other ophthalmic diseases |
| US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| DK1761266T3 (da) * | 2004-05-25 | 2013-08-05 | Galderma Pharma Sa | Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme |
| US20070203144A1 (en) * | 2006-01-17 | 2007-08-30 | Allergan, Inc. | Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals |
| US7323477B2 (en) * | 2006-02-02 | 2008-01-29 | Allergan, Inc. | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline |
| RU2321399C1 (ru) * | 2006-06-01 | 2008-04-10 | Федеральное государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт Федерального агентства по здравоохранению и социальному развитию" | Способ лечения больных розацеа |
| US20090005450A1 (en) * | 2007-04-09 | 2009-01-01 | Belinda Tsao Nivaggioli | Use of creatine compounds for the treatment of eye disorders |
| US20090061020A1 (en) * | 2007-08-31 | 2009-03-05 | Theobald Klaus P | Brimonidine Compositions for Treating Erythema |
| US8455548B2 (en) * | 2007-10-18 | 2013-06-04 | Allergan, Inc. | Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists |
| US8293742B2 (en) * | 2008-08-01 | 2012-10-23 | Alpha Synergy Development, Inc. | Preferential vasoconstriction compositions and methods of use |
| US20100203165A1 (en) * | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
| FR2942138A1 (fr) * | 2009-02-16 | 2010-08-20 | Galderma Res & Dev | Association de composes pour le traitement ou la prevention des affections dermatologiques |
| US20110224216A1 (en) * | 2009-10-26 | 2011-09-15 | Galderma Laboratories Inc. | Methods of Treating or Preventing Acute Erythema |
| US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| AU2011231543B2 (en) * | 2010-03-26 | 2015-01-15 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of erythema |
| CA2792649A1 (en) * | 2010-03-26 | 2011-09-29 | Michael Graeber | Improved methods and compositions for safe and effective treatment of telangiectasia |
| EP2600832A1 (en) * | 2010-08-06 | 2013-06-12 | Galderma Research & Development | Combination of compounds for treating or preventing skin diseases |
-
2012
- 2012-08-11 UA UAA201406109A patent/UA109359C2/ru unknown
- 2012-11-08 RU RU2017131492A patent/RU2667645C1/ru active
- 2012-11-08 SG SG10201609145PA patent/SG10201609145PA/en unknown
- 2012-11-08 EP EP20193075.7A patent/EP3763370A1/en not_active Withdrawn
- 2012-11-08 DK DK12784857.0T patent/DK2776034T3/en active
- 2012-11-08 MX MX2014005640A patent/MX350662B/es active IP Right Grant
- 2012-11-08 JP JP2014541225A patent/JP6359456B2/ja active Active
- 2012-11-08 EP EP12784857.0A patent/EP2776034B1/en active Active
- 2012-11-08 SG SG10201809506TA patent/SG10201809506TA/en unknown
- 2012-11-08 CN CN201280065945.0A patent/CN104136029A/zh active Pending
- 2012-11-08 WO PCT/US2012/064075 patent/WO2013070861A1/en not_active Ceased
- 2012-11-08 MY MYPI2014001376A patent/MY182553A/en unknown
- 2012-11-08 ES ES12784857.0T patent/ES2635421T3/es active Active
- 2012-11-08 CA CA2855005A patent/CA2855005C/en active Active
- 2012-11-08 EP EP17156230.9A patent/EP3184110B1/en active Active
- 2012-11-08 RU RU2014122758A patent/RU2630978C2/ru active
- 2012-11-08 PH PH1/2014/501051A patent/PH12014501051A1/en unknown
- 2012-11-08 AU AU2012335803A patent/AU2012335803B2/en not_active Ceased
- 2012-11-08 US US13/672,475 patent/US20130123303A1/en not_active Abandoned
- 2012-11-08 KR KR1020147015533A patent/KR102004563B1/ko not_active Expired - Fee Related
- 2012-11-08 BR BR112014011336A patent/BR112014011336A2/pt not_active Application Discontinuation
- 2012-11-08 SG SG11201402246RA patent/SG11201402246RA/en unknown
- 2012-11-09 TW TW108123351A patent/TW202014189A/zh unknown
- 2012-11-09 TW TW101141967A patent/TWI580424B/zh active
- 2012-11-09 TW TW106103338A patent/TWI708604B/zh not_active IP Right Cessation
- 2012-11-12 AR ARP120104260A patent/AR088845A1/es unknown
-
2014
- 2014-05-07 IL IL232483A patent/IL232483B/en active IP Right Grant
- 2014-05-12 CL CL2014001242A patent/CL2014001242A1/es unknown
- 2014-05-12 ZA ZA2014/03396A patent/ZA201403396B/en unknown
-
2015
- 2015-05-01 US US14/702,219 patent/US9308201B2/en active Active
- 2015-10-30 US US14/927,948 patent/US20160051534A1/en not_active Abandoned
-
2016
- 2016-08-17 AU AU2016216627A patent/AU2016216627B2/en not_active Ceased
- 2016-11-16 US US15/353,262 patent/US20170095466A1/en not_active Abandoned
-
2017
- 2017-05-08 JP JP2017092572A patent/JP6526737B2/ja active Active
-
2018
- 2018-08-21 IL IL261269A patent/IL261269A/en unknown
-
2019
- 2019-08-18 IL IL26875719A patent/IL268757A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017149767A5 (cg-RX-API-DMAC7.html) | ||
| MX2024010140A (es) | Nuevos metodos. | |
| Shankar et al. | A clinical trial for evaluation of leech application in the management of Vicarcikā (Eczema) | |
| Tfelt-Hansen et al. | Nonsteroidal antiinflammatory drugs in the acute treatment of migraine | |
| RU2015128265A (ru) | Способы лечения зуда | |
| NZ597534A (en) | Method for treating a patient in need of aspirin therapy | |
| RU2013122987A (ru) | Способ лечения комбинированного радиационно-термического поражения | |
| JP2016501219A5 (cg-RX-API-DMAC7.html) | ||
| Paulis et al. | Rationale of combination therapy with antioxidants in medical management of Peyronie’s disease: results of clinical application | |
| Nagasu et al. | Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity | |
| FR2961695A1 (fr) | Utilisation de composes dans le traitement ou la prevention de troubles cutanes | |
| JP2014533271A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2021055493A5 (cg-RX-API-DMAC7.html) | ||
| RU2019110264A (ru) | Циклическое соединение | |
| Sharquie et al. | Therapeutic evaluation of 2% tea lotion in comparison with 5% zinc sulfate solution in the treatment of acne rosacea | |
| RU2014122758A (ru) | Фармацевтические составы для лечения заболеваний и состояний кожи, содержащие 7-(1н-имидазол-4-илметил)-5,6,7,8-тетрагидрохинолин | |
| Joshi et al. | Tissue debridement effect of Apamarga kshara taila and adjuvant medications in the management of nonhealing venous ulcer: A case series | |
| Omisanjo et al. | Clinical characteristics and outcome of management of Fournier′ s gangrene at the Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria | |
| Bonamonte et al. | Aquatic skin diseases from chemical and physical causes | |
| Lee et al. | Burn wound successfully treated with 830-nm light emitting diode phototherapy combined with epidermal growth factor solution | |
| WO2023019095A3 (en) | Momelotinib combination therapy | |
| MX2023013514A (es) | Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga. | |
| Mansouri et al. | Twenty-four-hour intraocular pressure patterns in a symptomatic patient after ab interno trabeculotomy surgery | |
| Gazewood et al. | Ivermectin 1% cream (soolantra) for inflammatory lesions of rosacea | |
| Godse et al. | “Busting” urticaria with a “burst” of steroids |